Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence

Travel Med Infect Dis. 2020 May-Jun:35:101710. doi: 10.1016/j.tmaid.2020.101710. Epub 2020 Apr 28.

Authors

Kapil Khambholja¹, Deepak Asudani²

Affiliations

¹ Genpro Research Pvt Ltd, Technopark Campus, Thiruvananthapuram, Kerala, 695581, India. Electronic address: [email protected].
² Department of Medicine, Division of Hospital Medicine, University of California, San Diego, 92103, USA. Electronic address: [email protected].

No abstract available

Publication types

Letter
Comment

MeSH terms

Adenosine Monophosphate / analogs & derivatives
Alanine / analogs & derivatives
Amides
Betacoronavirus*
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections* / drug therapy
Humans
Pandemics*
Pneumonia, Viral*
Pyrazines
SARS-CoV-2

Substances

Amides
Pyrazines
remdesivir
Adenosine Monophosphate
favipiravir
Alanine